Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
This agreement is in addition to the $92 million filling line expansion announced in November 2021
New logo reflects Thyrocare’s transformation since 1996 to its current leading position at the cutting edge of Diagnostic services
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Subscribe To Our Newsletter & Stay Updated
